hotspot -WSS

hotspot

author：knowledge 2025-09-30 12:17:00 - browse：6678

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The science behind Janet Jackson's pregnancy at 49

entertainment

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

What would happen to your eyes if you looked at the solar eclipse?

Why we need to separate burnout from moral injury in health care

'Weather

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

hotspot

hotspot

Affirmative action in medical school literally saved lives

Death of patient in Alzheimer’s trial raises question of possible risks

After affirmative action ruling, medical educators look to 'holistic review'

Adidas to release second batch of Yeezy sneakers after breakup with Ye

ChatGPT in medicine: STAT answers readers' burning questions

The strategy behind pharma's lawsuits over drug pricing reform

Malaria cases in Florida and Texas: Here’s what you need to know

Cloning humans is technically possible. It's curious no one has tried

Malaria cases in Florida and Texas: Here’s what you need to know

What AstraZeneca

explore

The battle over the Brookhaven Landfill on Long Island

WATCH: Why do fingernails fall off when they're damaged?

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

What AstraZeneca

With FDA staff opposed to Sarepta therapy, top official intervened

The battle over the Brookhaven Landfill on Long Island

entertainment

focus

explore

focus